The antimalarial efficacy and mechanism of resistance of the novel chemotype DDD01034957

Celia Miguel-Blanco1, James M. Murithi2, Ernest Diez Benavente3, Fiona Angrisano4, Katarzyna A. Sala5, Donelly A. van Schalkwyk3, Manu Vanaerschot2, Frank Schwach6, Matthew J. Fuchter7, Oliver Billker6,8, Colin J. Sutherland3, Susana G. Campino1, Taane G. Clark3, Andrew M. Blagborough4,5, David A. Fidock2,9, Esperanza Herreros1,10, Francisco Javier Gamo1, Jake Baum5 & Michael J. Delves3

New antimalarial therapeutics are needed to ensure that malaria cases continue to be driven down, as both emerging parasite resistance to frontline chemotherapies and mosquito resistance to current insecticides threaten control programmes. Plasmodium, the apicomplexan parasite responsible for malaria, causes disease pathology through repeated cycles of invasion and replication within host erythrocytes (the asexual cycle). Antimalarial drugs primarily target this cycle, seeking to reduce parasite burden within the host as fast as possible and to suppress recrudescence for as long as possible. Intense phenotypic drug screening efforts have identified a number of promising new antimalarial molecules. Particularly important is the identification of compounds with new modes of action within the parasite to combat existing drug resistance and suitable for formulation of efficacious combination therapies. Here we detail the antimalarial properties of DDD01034957—a novel antimalarial molecule which is fast-acting and potent against drug resistant strains in vitro, shows activity in vivo, and possesses a resistance mechanism linked to the membrane transporter PfABCI3. These data support further medicinal chemistry lead-optimization of DDD01034957 as a novel antimalarial chemical class and provide new insights to further reduce in vivo metabolic clearance.

Malaria, caused by Plasmodium parasites, remains a global disease of devastating morbidity and mortality. Despite recent successes in malaria control and eradication in the last two decades, progress has stalled, with an estimated 228 million cases and 405,000 deaths in 2018. Together with the emergence of artemisinin and partner drug resistance in Southeast Asia, there is a pressing need for new chemical classes of antimalarials with unique modes of action. In particular, molecules that are fast-acting and long-lasting are a priority for antimalarial development as they have the potential to rapidly reduce the parasite burden within an afflicted patient and provide protection against recrudescence (Target Candidate Profile 1).

Recently, P. falciparum asexual stages and male and female gametocytes were screened against a 70,000 compound diversity library identifying a number of new scaffolds for antimalarial drug development. One such compound, DDD01034957 (Fig. 1), was identified to possess a chemical scaffold not represented in previous

1Global Health, GlaxoSmithKline, Tres Cantos, 28760 Madrid, Spain. 2Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA. 3Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK. 4Division of Microbiology and Parasitology, Department of Pathology, Cambridge University, Tennis Court Road, Cambridge CB2 1QG, UK. 5Department of Life Sciences, Imperial College London, South Kensington, London SW7 2AZ, UK. 6Parasites and Microbes Programme, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK. 7Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, White City Campus, Wood Lane, London W12 0BZ, UK. 8Department of Molecular Biology, The Laboratory for Molecular Infection Medicine Sweden (MIMMS), Umeå University, 901 87 Umeå, Sweden. 9Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA. 10Present address: Medicines for Malaria Venture, 20 Route de Pré-Bois, 1215 Geneva 15, Switzerland. *email: michael.delves@lshtm.ac.uk
As a novel chemotype, together with its reported IC\textsubscript{50} against \textit{P. falciparum} asexual parasites (but not gametocytes), this compound was identified as a promising hit molecule and therefore prioritised for further study.

Here we perform a detailed in vitro and in vivo characterisation of the antimalarial and pharmacokinetic properties of DDD01034957 using three different \textit{Plasmodium} species, test for development of resistance in vitro and perform structure–function studies of analogues which share the same chemical scaffold.

**Results**

**DDD01034957 shows no cross-resistance to a range of drug resistant \textit{P. falciparum} strains.** The use of partner drugs in combination therapies requires two molecules with distinct modes of action to protect against the emergence of resistance to the monotherapy. To determine whether DDD01034957 has a unique mode of action or acts through an already recognised mechanism, its efficacy was tested in asexual growth assays against a range of selection-derived drug resistant \textit{P. falciparum} parasites and their parental non-resistant lines (Table 1). In all assays, the resistant strains were sensitive to DDD01034957, giving no greater than a threefold increase in IC\textsubscript{50} when compared to their parental lines. This result suggests that DDD01034957 has a distinct mode of resistance and is active against parasites harbouring resistance mutations linked to a loss of efficacy against many new antimalarials currently under clinical development.

| Target/pathway | Parent line | Mutant/transformed strain | DDD01034957 fold change in IC\textsubscript{50} |
|----------------|-------------|---------------------------|-----------------------------------------------|
| PfATP4         | 3D7         | 3D7-C9-ATP4F917L\textsuperscript{5} | 0.83 ± 0.03                                    |
|                | W2          | W2-ATP4F412L\textsuperscript{6} | 1.65 ± 0.20                                    |
|                | W2          | W2-ATP4V178I\textsuperscript{7} | 1.47 ± 0.35                                    |
| PfCARL         | 3D7         | 3D7-C9-CARL-E834D\textsuperscript{8} | 0.83 ± 0.11                                    |
|                | 3D7         | 3D7-C9-CARL-Q821H\textsuperscript{9} | 1.16 ± 0.13                                    |
| PfPHK          | Dd2         | Dd2-PH4-K1319V\textsuperscript{10} | 1.0 ± 0.08                                     |
| ETC            | Dd2         | Dd2-HATB_yeastDHODH\textsuperscript{11} | 0.90 ± 0.06                                    |
| Folate Biosynthesis | 3D7 | 3D7 adapted to grow in ↓pABA/FAC\textsuperscript{12} | 2.96 ± 0.29                                    |

**DDD01034957 is a fast-acting antimalarial against \textit{P. falciparum} asexual stages in vitro.** Fast-acting antimalarials are crucial to rapidly reduce the parasite burden and relieve the patient from malarial symptoms as fast as possible\textsuperscript{11}. To determine the speed of action of DDD01034957, it was evaluated in an established parasite viability assay\textsuperscript{12} and compared to artemisinin (fast kill), chloroquine (fast kill), pyrimethamine (medium kill) and atovaquone (slow kill)\textsuperscript{12}. At 3.2 μM (10IC\textsubscript{50}), DDD01034957 rapidly reduced parasite viability to baseline within 24 h at a similar rate to 10IC\textsubscript{50} artemisinine and chloroquine (Fig. 2), thus demonstrating its fast-acting antimalarial activity. In contrast, the slower acting antimalarials pyrimethamine and atovaquone showed only partial reduction in parasite viability at 24 h.
The R2180P mutant was 29.8-fold less susceptible to DDD01034957 than the parental mutation (the amino acid adjacent to the H2181D mutation observed in this study) and a pfabci3 copy number is mediated by PfABCI3, this compound was tested against a previously reported line harbouring a R2180P which may form part of the transporter channel (Fig. 3C). To determine whether DDD01034957 resistance mutations map to a region of the ABCI3 protein that is predicted to harbour multiple transmembrane domains possessed a H2181D mutation and the remaining clone acquired a L79F mutation. The F2010L and H2181D sive expression of its gene product, liver stage antigen 1, at only the liver stages of the parasite life cycle13. The observed, it was discounted as a potential mode of action/mechanism of resistance due to the reported exclu-

Although each clone possessed up to two different mutations in from a combination of six mutations pflsa1 (PF3D7_0319700) and pflsa1 pfabci3 (Fig. 3A, Supplementary Table 1). Whole-genome sequencing highlighted two genes in common that possessed a H2181D mutation and the remaining clone acquired a L79F mutation. The F2010L and H2181D mutations map to a region of the ABCI3 protein that is predicted to harbour multiple transmembrane domains which may form part of the transporter channel (Fig. 3C). To determine whether DDD01034957 resistance is mediated by PfABCI3, this compound was tested against a previously reported line harbouring a R2180P mutation (the amino acid adjacent to the H2181D mutation observed in this study) and a pfabci3 copy number variant (CNV) (Fig. 3B)12. The R2180P mutant was 29.8-fold less susceptible to DDD01034957 than the parental strain, while the CNV line displayed 5.3-fold decreased susceptibility. Together, these data strongly suggest that PfABCI3 does indeed mediate resistance to DDD01034957.

A combined dataset of 6,230 sequenced P. falciparum isolates from 22 countries16–18 was searched and none of the identified mutations in pfabci3 conferring DDD01034957 resistance were found. Similarly, evidence of pfabci3 CNV was only found in 0.89% of isolates, which possessed duplications of different lengths implying independent events rather than selection pressure at this locus. This implies that an optimised scaffold of DDD01034957 would not encounter existing PfABCI3-mediated resistance in the clinic.

In vitro selection of P. falciparum clones resistant to DDD01034957 identifies pfabci3 as a mediator of resistance. To identify the mode of action of DDD01034957 and/or identify a mechanism of resistance, drug resistant parasites were selected in vitro by pulsing P. falciparum asexual blood stage cultures with DDD01034957 at 0.2 µM and 2 µM. Approximately three weeks later, the resistant parasite population were serially diluted to derive clonal parasite lines with distinct genotypes. Eleven clones from three independent selection experiments were isolated and, of the nine tested, all showed a 11.5- to 26.2-fold increase in IC50 (Fig. 3A, Supplementary Table 1). Whole-genome sequencing highlighted two genes in common that possessed a variety of single point mutations in all eleven clones—pfabci3 (PF3D7_0319700) and pfsa1 (PF3D7_10364000). Although each clone possessed up to two different mutations in pfsa1 from a combination of six mutations observed, it was discounted as a potential mode of action/mechanism of resistance due to the reported exclusive expression of its gene product, liver stage antigen 1, at only the liver stages of the parasite life cycle13. The remaining gene pfabci3 encodes an essential ATP-binding cassette transport protein that is known to mediate resistance to other experimental antimalarial compounds. These compounds encompass several distinct chemical scaffolds14,15 unrelated to DDD01034957. Eight out of eleven clones harboured the mutation F2010L, two possessed a H2181D mutation and the remaining clone acquired a L79F mutation. The F2010L and H2181D mutations map to a region of the ABCI3 protein that is predicted to harbour multiple transmembrane domains which may form part of the transporter channel (Fig. 3C). To determine whether DDD01034957 resistance is mediated by PfABCI3, this compound was tested against a previously reported line harbouring a R2180P mutation (the amino acid adjacent to the H2181D mutation observed in this study) and a pfabci3 copy number variant (CNV) (Fig. 3B)12. The R2180P mutant was 29.8-fold less susceptible to DDD01034957 than the parental strain, while the CNV line displayed 5.3-fold decreased susceptibility. Together, these data strongly suggest that PfABCI3 does indeed mediate resistance to DDD01034957.

A combined dataset of 6,230 sequenced P. falciparum isolates from 22 countries16–18 was searched and none of the identified mutations in pfabci3 conferring DDD01034957 resistance were found. Similarly, evidence of pfabci3 CNV was only found in 0.89% of isolates, which possessed duplications of different lengths implying independent events rather than selection pressure at this locus. This implies that an optimised scaffold of DDD01034957 would not encounter existing PfABCI3-mediated resistance in the clinic.

Determining the in vivo efficacy and pharmacokinetic properties of DDD01034957. Having established in vitro antimalarial efficacy, the in vivo efficacy of DDD01034957 was investigated using the standard 4-day suppression test in the Plasmodium berghei rodent model of infection19. A 50 mg/kg oral dose of DDD01034957 administered on four consecutive days to infected mice reduced parasitaemia by 59.7–79.8% compared to the vehicle control (Fig. 4A). However, at this level of suppression DDD01034957 did not appear to protect mice from the symptoms of malaria and there was no statistically significant difference in time taken for mice to reach their humane endpoint (unpaired t-test). In contrast, the 10 mg/kg chloroquine treatment completely suppressed parasitaemia and all mice survived to the end of the experiment. Whole blood levels of DDD01034957 in naïve mice treated with a 50 mg/kg dose by intraperitoneal (IP) injection rapidly peaked at 1092 ng/ml but reduced with an elimination half-life of ~106 min suggesting a rapid clearance mechanism (Fig. 4B).

In vitro antimalarial structure–activity relationship. It was hypothesised that the methoxy group on the phenyl ring of DDD01034957 could be a potential metabolic liability and partly account for its fast in vivo clearance following metabolic cleavage of the methyl group. Therefore, commercially available analogues
in which the methoxy group was shifted, deleted, or replaced with polar halogens in a variety of positions were purchased and tested for in vitro activity against *P. falciparum* asexual parasites (Fig. 5). Despite having the same number of hydrogen bond donors and acceptors, moving the methoxy group from the meta to para position (MolPort-005-956-270 and MolPort-005-956-243) completely abrogated antimalarial activity. Similarly, halogen substitution of the para-methoxy group was not active (Molport-005-956-271 and MolPort-005-956-242), whilst the meta (Molport-006-806-851, MolPort-006-819-388 and MolPort-005-956-265) and ortho (Molport-006-818-789) substitutions retained low micromolar activity. Removing the methoxy group altogether also greatly reduced antimalarial activity (MolPort-008-120-629 and MolPort-006-386-365) suggesting that the methoxy group of DDD01034957 may be important for target binding. Conversely, replacement of the five-membered amine ring with a six-membered ring did not appreciably modify activity suggesting that at least small changes of this part of the molecule are tolerated, and further alterations will need to be investigated. DDD01034957 is more efficacious against *P. falciparum* than *P. knowlesi*. It has been established that some antimalarials show different efficacy against different species of *Plasmodium*⁵. Therefore, the antimalarial activity of DDD01034957 was tested on culture adapted *Plasmodium knowlesi*—a species causing malaria in humans and primates common in Southeast Asia. Over one asexual cycle (48 h *P. falciparum* vs. 27 h *P. knowlesi*), DDD01034957 showed greatly reduced potency against *P. knowlesi* with inhibition not reaching an upper plateau by the maximum concentration tested (40 µM) (Fig. 6).

**Discussion**

Herein, we report the in vitro and in vivo efficacy of DDD01034957 together with its mechanism of resistance mediated through the transporter PfABC13. DDD01034957 demonstrates promising fast-acting killing of *P. falciparum* asexual blood stage parasites in vitro, and shows efficacy against parasite lines harbouring resistance to many diverse antimalarials. These data support the continued development of DDD01034957 as a new chemotype with antimalarial potential. However, DDD01034957 had limited in vivo efficacy against *P. berghei*. Whole blood concentrations peaked at 25-times the in vitro IC₅₀ and maintained levels of DDD01034957 above the IC₅₀ for at least 480 min (the last time point sampled), indicating that lack of efficacy may not be due to bioavailability, but in part may be related to fast clearance. Interestingly however, the *pfabc1* gene harbours the equivalent histidine to aspartate point mutation that gave the ~12-fold increase in IC₅₀ in the *P. falciparum* H2181D resistant line, suggesting that the *P. berghei* line tested may be naturally resistant to DDD01034957. Consequently, future work should prioritise studying in vivo efficacy of DDD01034957 in the humanised *P.
falciparum mouse model or alternatively in a P. berghei line modified transgenetically to contain the D2181H reverting mutation. DDD01034957 lacked efficacy against P. knowlesi which does not contain any of the point mutations in pkabci3 linked to resistance in P. falciparum. It has previously been reported that P. knowlesi shows modulated sensitivity to a range of different antimalarials when compared to P. falciparum. Currently it is unclear as to why this phenomenon occurs. However P. falciparum possesses a number of species-specific influx/efflux transporters that might play an important role in modulating the uptake of DDD01034957 from the red blood cell. Alternatively, DDD01034957 efficacy could be linked to different binding affinities to its target, which might differ between Plasmodium species.

A preliminary structure–activity relationship (SAR) study using commercially available analogues indicates that modification of the methoxy group of DDD01034957 substantially impacted its antimalarial activity. Replacement with a fluorine or chlorine atom results in a reduced activity by 10- to 14-fold respectively. Deeper medicinal chemistry studies are required to determine whether metabolism of the methoxy group to a phenol is important for in vivo clearance. Key to such studies could be the synthesis and testing of phenol analogues of our series and/or methoxy surrogates. Additional future medicinal chemistry could include exploration of whether modification of the pyrido-pyrimidinone core can increase efficacy, while improving pharmacokinetics.

In conclusion, a detailed study of the antimalarial efficacy of new chemotypes is highly valuable for the progression of molecules into the lead optimisation stage. DDD01034957 shows promising in vitro activity and demonstrated, albeit reduced, oral in vivo efficacy (which is unsurprising for a non-optimised primary hit at this preliminary stage). Its mode of action is potentially distinct from other antimalarials under development and its mechanism of resistance is now defined, implicating the transporter PfABCI3 in drug influx/efflux. Future work will focus on reducing in vivo metabolic clearance, further improving efficacy, and mitigating PfABCI3-mediated resistance.

Materials and methods
Comparison of resistant strains. The asexual activity of published drug resistant strains (Table 1) were tested in the P. falciparum lactate dehydrogenase assay (pLDH) which is a surrogate for asexual parasite growth. Each strain was tested in comparison to its parental (non-resistant) line. Parasites were prepared at 0.25% parasitaemia/2% haematocrit in RPMI-1640 supplemented with 5% Albumax and 150 µM hypoxanthine (except the parasite strain adapted to low folate conditions which was cultured in culture medium depleted of paraaminobenzoic acid and with low (100 ng/ml) folic acid concentrations) before being dispensed into wells of a 384 well plate (25 µl per well) containing test compounds in DMSO. After incubation for 72 h at 37 °C under a 5% CO2/5% O2/90% N2 atmosphere, the plates were frozen at −70 °C to lyse cells. After thawing, 70 µl of reaction
solution (100 mM sodium l-lactate, 100 mM 3-acetylpyridine adenine dinucleotide (APAD), 125 µM NitroBlue tetrazolium (NBT), 200 µl ml⁻¹ diaphorase, 0.5% tween 20, 100 mM Tris–HCl pH 8) were added to each well and mixed. pLDH activity was then measured by monitoring NBT reduction by absorbance at 650 nm using a plate reader.

**Speed of kill assay.** This assay was performed as described in Linares et al.²². Briefly, *P. falciparum* 3D7 strain parasites were incubated at 2% haematocrit, 0.5% parasitaemia in 96 well plates in the presence of test compounds at 10xIC₅₀. At 24 and 48 h post drug treatment parasite samples were transferred and diluted into
fresh erythrocytes labelled with 10 µM of the fluorophore carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) and incubated for a subsequent 48 h. Parasites were then labelled with 2 µM Hoechst 33342 and the proportion of viable parasites that had reinvaded the fresh erythrocytes (i.e. CFDA-SE-positive erythrocytes containing Hoechst 33342-positive parasites) after 24/48 h drug pulse determined by FACS analysis.

**Evolution and testing of drug resistance.** A *P. falciparum* line showing an accelerated 38 h asexual life cycle (3D7 IG06—a gift from Daniel Goldberg, Washington University School of Medicine in St Louis) was used for drug selection experiments. Selection of compound-resistant lines was performed using a high-pressure intermittent method6. 1 × 10⁹ asexual parasites were cultured in the presence of 0.2 µM or 2 µM DDD01034957 and monitored regularly until parasitaemia recrudesced (11–15 days). Then, compound pressure was removed to allow cultures to expand up to ~ 2% parasitaemia, DDD01034957 was added again and sensitivity was compared to the parental line. Resistant parasites were then cloned by limiting dilution to obtain up to six clones per selection experiment (n = 3).

The sensitivity of a PfABCI3 copy number variant (CNV) and PfABCI3 R2180P14,15 mutant to DDD01034957 was tested in asexual growth assays. Parasites were maintained at 3% haematocrit with human O + red blood cells in RPMI medium supplemented with 50 µM hypoxanthine, 2 g/l sodium bicarbonate, 2 mM L-glutamine, 25 mM HEPES, 0.5% AlbuMAXII (Invitrogen) and 10 µg/ml gentamycin in 5% O₂, 5% CO₂ and 90% N₂ at 37 °C. Parasites were diluted to 0.3% parasitaemia/1% haematocrit in 96 well plates containing serial dilutions of DDD01034957 and incubated for 72 h at 37 °C. Parasite survival in each well was assessed by SYBR Green and MitoTracker Deep Red FM staining (Life Technologies) and subsequent flow-cytometric analysis (Accuri C6, BD Biosciences).

**Whole genome sequencing.** Resistant parasite cultures were pelleted by centrifugation and then frozen at – 80 °C to lyse the cells. Genomic DNA was then extracted using a Blood & Cell Culture DNA Mini Kit (Qiagen) and sequenced together on one lane of an Illumina HiSeqX machine with a 150 bp paired end protocol. The resulting sequences were mapped to the 3D7 reference genome (v3) using bwa-mem software, and genomic variants called using GATK and samtools software tools within existing bioinformatic pipelines23. A collection of genomes from 6230 *P. falciparum* isolates from 22 countries16–18, was searched for identified PfABCI3 mutations. The same dataset was analysed for evidence of CNV using Delly24 with a < 200 kbp cut-off.

**P. berghei 4-day suppression test.** All procedures were performed in accordance with the UK Animals (Scientific Procedures) Act (PPL 70/8788) and approved by the Imperial College and University of Cambridge AWERB. The Office of Laboratory Animal Welfare Assurance for Imperial College covers all Public Health Service supported activities involving live vertebrates in the US (no. A5634-01). This study was carried out in compliance with the ARRIVE guidelines (https://arriveguidelines.org/). Naïve T0 mice (n = 5 per treatment) were infected by IP injection of 2 × 10⁷ *P. berghei* parasites obtained from the blood of a donor mouse. DDD01034957 and chloroquine (positive control) were dissolved in 7% Tween 80/3% Ethanol in dH₂O and dosed orally to infected mice to result in a 50 mg/kg and 10 mg/kg exposure respectively. Five additional infected mice received a vehicle-only dose as a negative control. Infected mice then received identical doses of drugs/vehicle 24, 48 and 72 h after infection and commencing at 96 h post-infection, were smeared daily to monitor parasitaemia. Mice reached their humane endpoint immediately upon showing outward pathological indicators of malarial infection and were considered cured if this was not reached by day 30 post-infection.

**Mouse in vivo PK analysis.** Pharmacokinetic analysis was outsourced commercially to Dundee Drug Discovery Unit (DDU). Briefly, DDD01034957 was dissolved in 7% Tween 80/3% Ethanol in dH₂O and dosed orally to infected mice to result in a 50 mg/kg and 10 mg/kg exposure respectively. Whole blood was sampled at intervals over 8 h and the concentration of DDD01034957 determined by mass spectroscopy.

**Analogue asexual growth assays.** *P. falciparum* 3D7 strain parasites were synchronised by sorbitol lysis to obtain a pure ring stage population and maintained in RPMI 1640 supplemented with 25 mM HEPES, 25 mM...
NaHPO₄, 10 mM D-glucose, 2 mM L-glutamine, 50 mg/L hypoxanthine, 25 mg/L gentamicin sulphate, 5 g/L Albumax II. Parasites were diluted to 2% parasitaemia and 1% haematocrit before being cultured in 96 well plates containing serial dilutions of DDD01034957 and analogue compounds. Wells containing DMSO served as a negative control and wells containing 100 nM dihydroartemisinin served as a positive control. Parasites were maintained at 37 °C under a gas mixture of 96% N₂, 3% O₂ and 1% CO₂ for 72 h before plates were frozen at –80 °C overnight. Thawed plates were lysed in SYBR green lysis buffer (20 mM Tris, 5 mM EDTA, 0.008% (w/v) saponin, 0.08% (v/v) Triton X-100, pH 7.5 + 1:10,000 SYBR Green I). After 1 h incubation at 37 °C, plates were read in a fluorescence plate reader at 490 nm excitation and 520 nm emission. Percentage inhibition of asexual parasite growth was calculated with respect to the positive and negative controls.

P. falciparum vs. P. knowlesi asexual assay comparison. P. falciparum 3D7 strain and P. knowlesi A1–H.1 strain were maintained in RPMI 1640 supplemented with 25 mM HEPES, 25 mM NaHPO₄, 10 mM D-glucose, 2 mM L-glutamine, 50 mg/L hypoxanthine, 25 mg/L gentamicin sulphate, 5 g/L Albumax II and 10% (v/v) equine serum (Pan Biotech, P30-0702). Both species were cultured in human A+ erythrocytes diluted to 1% haematocrit and 1% parasitaemia in 96 well plates containing serial dilutions of DDD01034957. Assays were run for one asexual cycle (48 h P. falciparum; 27 h P. knowlesi) before being frozen at –80 °C overnight. Thawed plates were lysed in SYBR green lysis buffer and fluorescence read as above.

Received: 23 November 2020; Accepted: 18 December 2020
Published online: 21 January 2021

References
1. WHO | World Malaria Report 2019. WHO https://www.who.int/publications/i/item/9789241565721
2. Burrows, J. N. et al. New developments in anti-malarial target candidate and product profiles. Malar. J. 16, 26 (2017).
3. Gamo, F.-J. et al. Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305–310 (2010).
4. Delves, M. J. et al. A high throughput screen for next-generation leads targeting malaria parasite transmission. Nat. Commun. 9, 3805 (2018).
5. Jiménez-Díaz, M. B. et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc. Natl. Acad. Sci. U.S.A. (2014).
6. Corey, V. C. et al. A broad analysis of resistance development in the malaria parasite. Nat. Commun. 7, 11901 (2016).
7. Magistrado, P. A. et al. Plasmodium falciparum cyclic amine resistance locus (PiCARL), a resistance mechanism for two distinct compound classes. ACS Infect. Dis. 2, 816–826 (2016).
8. Paquet, T. et al. Antimalarial efficacy of MMVJ390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Transl. Med. 9, (2017).
9. Painter, H. J., Morrisey, J. M. & Vaidya, A. B. Mitochondrial Electron Transport Inhibition and Viability of Intraerythrocytic Plasmodium falciparum. Antimicrob. Agents Chemother. 54(12), 5281–5287 (2010).
10. Raphemot, R., Lafuente-Monasterio, M. J., Gamo-Benito, F. J., Clardy, J. & Derbyshire, E. R. Discovery of dual stage malaria inhibitors with new targets. Antimicrob. Agents Chemother. 60(3), 1430–1437 (2015).
11. Saini, L. M. et al. P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS ONE 7, e30949 (2012).
12. Linares, M. et al. Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay. Malar. J. 14, 441 (2015).
13. Fidock, D. A. et al. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J. Immunol. 153, 190–204 (1999).
14. Kenthirapalan, S., Waters, A. P., Matuschewski, K. & Kooij, T. W. A. Functional profiles of orphan membrane transporters in the life cycle of the malaria parasite. Nat. Commun. 7, 10519 (2016).
15. Cowell, A. N. et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science 359, 191–199 (2018).
16. Anambua-Ngwaa, A. et al. Major subpopulations of Plasmodium falciparum in sub-Saharan Africa. Science 365, 813–816 (2019).
17. Jefferson, W. L. et al. Evolution and expansion of multidrug-resistant malaria in southeast Asia: A genomic epidemiology study. Lancet. Infect. Dis 19, 943–951 (2019).
18. Pearson, R. D., Amato, R., Kwiatkowski, D. P. & Project, M. P. falciparum C. An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. bioRxiv 824730 (2019) doi:https://doi.org/10.1101/824730.
19. Fidock, D. A., Rosenthal, P. J., Croft, S. L., Brun, R. & Nwaka, S. Antimalarial drug discovery: Efficacy models for compound screening. Nat. Rev. Drug. Discov. 3, 509–520 (2004).
20. van Schalkwyk, D. A. et al. Plasmodium knowlesi exhibits distinct in vitro drug susceptibility profiles from those of Plasmodium falciparum. Int. J. Parasitol. Drugs Drug Resist. 9, 93–99 (2019).
21. Benavente, E. D. et al. A reference genome and methylome for the Plasmodium knowlesi A1–H.1 line. Int. J. Parasitol. 48, 191–196 (2018).
22. Linares, M. et al. Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay. Malar. J. 14, 1 (2015).
23. Benavente, E. D. et al. Global genetic diversity of var2csa in Plasmodium falciparum with implications for malaria in pregnancy and vaccine development. Sci. Rep. 8, 15429 (2018).
24. Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333–i339 (2012).

Acknowledgements
This work was supported by funding from the Bill & Melinda Gates Foundation (Grant OPP1043501) and Medicines for Malaria Venture (Grant MMV08/2800). MJD acknowledges funding support from the Wellcome Trust ISSF fund. JB is supported by an Investigator Award from the Wellcome Trust (100993/Z/13/Z). SC is funded by BloomsburySET, Medical Research Council UK (MR/M01360X/1, MR/R025576/1, and MR/R020973/1) and...
BBSRC (Grant no. BB/R013063/1) grants. TGC is funded by the Medical Research Council UK (Grant no. MR/M01360X/1, MR/N010469/1, MR/R025576/1, and MR/R020973/1) and BBSRC (Grant no. BB/R013063/1). AMB thanks the MRC (MR/N00227X/1), Isaac Newton Trust, Alborada Fund, Wellcome Trust ISSF and University of Cambridge JRG Scheme, GHIT and the Royal Society for funding. DAF acknowledges funding support from the Bill & Melinda Gates Foundation (Malaria Drug Accelerator Consortium, PI Dr. Elizabeth Winzeler). CJS is supported by Public Health England, the UK Medical Research Council and the European Developing Countries Trials Platform. DAvS was funded by the Medicines for Malaria Venture Grant RD/15/0017. OB received funding from a Wellcome core Grant 206194/Z/17/Z to the Sanger Institute.

**Author contributions**

M.J.D., J.B., F.J.G., E.H. and C.M.B. conceived this study. C.M.B. performed the speed of kill assay, resistant strains analysis and in vitro drug selection. C.M.B. and M.J.D. prepared drug resistant parasites for W.G.S., which was performed by F.S. and O.B. E.D.B., C.S., S.G.C. and T.G.C. processed and analysed the whole genome sequencing data and performed bioinformatic analysis. J.M.M., M.V. and D.A.F. evaluated the efficacy of DDD01034957 against establish PfABCI3 mutant strains. F.A., K.S. and A.M.B. performed mouse in vivo Pb analysis. Dv.S. observed the efficacy comparison between Pf and Pb. M.J.F. and M.J.D. selected and tested the analogues of DDD01034957 for evaluation. M.J.D. drafted the manuscript and all authors approved the manuscript before submission.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-81343-z.

**Correspondence** and requests for materials should be addressed to M.J.D.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021